

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

INSIDE INFORMATION

ENTERING INTO A COMMERCIAL COOPERATION AGREEMENT WITH NOVARTIS PHARMA TECHNOLOGY (ZHEJIANG) CO., LTD.

This announcement is made by China Isotope & Radiation Corporation (the “**Company**”) pursuant to Rule 13.09(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that HTA Co., Ltd. (“**HTA**”), a subsidiary of the Company, has formally entered into a commercial cooperation agreement (the “**Commercial Cooperation Agreement**”) in relation to Pluvicto® (lutetium [¹⁷⁷Lu] vipivotide tetraxetan injection) with Novartis Pharma Technology (Zhejiang) Co., Ltd. (“**Novartis**”). Pluvicto® is the first and currently the only approved prostate-specific membrane antigen (“**PSMA**”)-targeted radioligand therapy in the PRC. It is primarily used for the treatment of advanced prostate cancer and is expected to provide patients with a new nuclear medicine therapeutic option that can prolong survival and improve quality of life in the future. The entering into of the Commercial Cooperation Agreement marks the commencement of strategic cooperation between the parties in respect of the innovative nuclear medicine product Pluvicto®. Leveraging its many years of compliant operational experience in the field of radiopharmaceuticals, HTA will work closely with Novartis to provide customised Pluvicto® product supply and related solutions to medical institutions and patients, thereby benefiting a broader patient population.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, as at the date of this announcement, Novartis and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Listing Rules). The Commercial Cooperation Agreement and the cooperation thereunder do not constitute a notifiable transaction under Chapter 14 of the Listing Rules or a connected transaction under Chapter 14A of the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Isotope & Radiation Corporation
Xiao Yafei
Chairman

Beijing, the PRC, 15 December 2025

As at the date of this announcement, the Board comprises Mr. Xiao Yafei, Mr. Zhang Junqi, Ms. Huo Yingying and Ms. Ma Xiaoyu as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.